Search results
www .actavis .com. Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
Aug 2, 2016 · Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Allergan plc (NYSE: AGN) today announced that Teva has completed its acquisition of Allergan’s generics business (“Actavis Generics”). This strategic acquisition brings together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines ...
Sep 12, 2023 · Actavis, Inc. was a global pharmaceutical business that was involved in the development, manufacturing, and distribution of its own brand named pharmaceuticals as well as the manufacture and distribution of generic pharmaceutical products, particularly a number of generic products from a company it had acquired, Watson Pharmaceuticals. The ...
Nov 23, 2014 · Actavis. shares for each share of . Allergan. common stock. Based on the closing price of . Actavis. shares on . November 14, 2014, the transaction is valued at approximately . $66 billion, or . $219. per . Allergan. share. The combination will create one of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro ...
Following its acquisition of Actavis, Teva now has around 340 product registrations pending FDA approval and holds the leading position in first-to-file opportunities, with approximately 115 abbreviated new drug applications pending in the US. In Europe, after divestitures, Teva will have a pipeline capable of sustaining over 5,000 launches.
Feb 18, 2014 · DUBLIN & NEW YORK--(BUSINESS WIRE)--Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that they have entered into a definitive agreement under which Actavis will ...
